- Home
- AKTX
as 06-26-2025 4:00pm EST
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 41.8M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 27.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.85 - $4.40 | Next Earning Date: | 08-18-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Akari Therapeutics plc ADS (AKTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gaslightwala Abizer | AKTX | President & CEO | Jun 23 '25 | Buy | $1.15 | 6,146 | $7,119.93 | 272,371 | |
| Gaslightwala Abizer | AKTX | President & CEO | Jun 20 '25 | Buy | $1.20 | 10,000 | $12,000.00 | 272,371 | |
| Gaslightwala Abizer | AKTX | President & CEO | Jun 17 '25 | Buy | $1.20 | 15,000 | $18,000.00 | 272,371 |
Latest Akari Therapeutics plc ADS News
AKTX Breaking Stock News: Dive into AKTX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent
Argus Research
2 days ago
Daily – Vickers Top Buyers & Sellers for 06/25/2025
MT Newswires
4 days ago
European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading
MT Newswires
9 days ago
European Equities Traded in the US as American Depositary Receipts Edge Higher Wednesday
GlobeNewswire
9 days ago
Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India
MT Newswires
10 days ago
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
GlobeNewswire
a month ago
Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology
GlobeNewswire
a month ago
Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
Compare AKTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AKTX Akari Therapeutics plc ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.